| Literature DB >> 31065209 |
Somrita Laha1, Prabhas P Giri1, Agnisekhar Saha1, Partha P Gupta2, Anisha De3.
Abstract
Malignant hyperthermia (MH) is an inherited, pharmacogenetic disorder of the skeletal muscle, characterized by dangerous hypermetabolic state after anesthesia with succinylcholine and/ or volatile halogenated anesthetic agents, clinically manifested as hyperpyrexia and related complications like tachycardia, tachypnea, increased carbon dioxide production, increased oxygen consumption, acidosis, rigid muscles, rhabdomyolysis and disseminated intravascular coagulation (DIC). Here we present a series of three cases of MH, admitted in our hospital in a span of 8 months for three different operative procedures to be done under general anesthesia (cleft lip repair, Duhamel's operation for Hirschsprung's disease and surgical repair of development dysplasia of hip), who developed probable hyperthermia owing to Halothane being used as an anesthetic agent. HOW TO CITE THIS ARTICLE: Laha S, Giri PP, Saha A, Gupta PP, De A. Life-threatening Episodes of Malignant Hyperthermia Following Halothane Anesthesia in Three Children: A Case Series and Review of Literature. Indian Journal of Critical Care Medicine, January 2019;23(1):47-50.Entities:
Keywords: Anesthesia; Dantrolene; Halothane; Malignant hyperthermia; Ryanodine receptor
Year: 2019 PMID: 31065209 PMCID: PMC6481263 DOI: 10.5005/jp-journals-10071-23112
Source DB: PubMed Journal: Indian J Crit Care Med ISSN: 0972-5229
Fig. 1Chest X-ray of case 1 showing pulmonary hemorrhage
Fig. 2MRI brain of case 1 showing multiple infarcts
Demographic and clinical profile of patients
| Age | 10 months | 1 year | 2.5 years |
| Sex | male | male | male |
| Halothane used | yes | yes | yes |
| Succinylcholine used | no | no | no |
| Previous exposure to halothane | no | yes | no |
| Development of symptoms following surgery | 40 min | 25 min | 30 min |
| Highest temperature | 107°F | 105.8°F | 106.6°F |
| Convulsions | yes | yes | yes |
| Hematuria | yes | yes | yes |
| Serum creatine phosphokinase (CPK) | 15970 U/L | 16400 U/L | 15200 U/L |
| Disseminated intravascular coagulation | yes | no | no |
| Acute kidney injury | yes | no | no |
| Ventilated | yes | yes | yes |
| Duration of ventilation | 21 days | 14 hours | 48 hours |
| Outcome | survived, severe global developmental delay | died | survived, no neuromotor deficit |